Logo

American Heart Association

  34
  0


Final ID:

Discussant

  • Morin, Daniel  ( Univ of CA San Francisco , San Francisco , California , United States )
  • Author Disclosures:
    Daniel Morin: DO have relevant financial relationships ; Consultant:Zoll:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Speaker:Zoll:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Featured Science in EP

Monday, 11/10/2025 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
Efficacy and safety of flecainide compared to amiodarone for atrial fibrillation cardioversion in patients with Coronary Artery Disease and preserved ejection fraction. FLECA-ED trial

Tsioufis Panagiotis-anastasios, Patsilinakos Sotirios, Kafkas Nikos, Tsioufis Konstantinos, Tsiachris Dimitris, Argyriou Nikolaos, Botis Michail, Kordalis Athanasios, Doundoulakis Ioannis, Antoniou Christos-konstantinos, Matthaiopoulos George, Zamanis Ioannis

Primary Results from the Post Approval Study of a Next Generation Wearable Cardioverter Defibrillator System: the ACE-PAS Trial

Poole Jeanne, Gleva Marye, Branch Kelley, Birgersdotter-green Ulrika, Doshi Rahul, Mahankali Sridhar Arun Raghav, Wang Melinda, Gustavson Laura, Zulueta Shirley

More abstracts from these authors:
Relationships Between Degree of Obesity, Transthoracic Impedance, and Cardioversion Efficacy

Sanchez Alexandra, Morin Daniel, Murphy Barret, Aymond Joshua, Bernard Michael, Hiltbold Aimee, Khatib Sammy, Polin Glenn, Rogers Paul, Castine Michael

You have to be authorized to contact abstract author. Please, Login
Not Available